<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39453261</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>08</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">234</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed9100234</ELocationID><Abstract><AbstractText>This study evaluated the factors influencing IgG/IgM antibody levels in 120 patients with head and neck cancer (HNC) following vaccination with inactivated SARS-CoV-2 vaccines. Each patient's demographic and clinical data were documented, and serum IgG and IgM antibodies were detected using a commercial magnetic chemiluminescence enzyme immunoassay kit. The results indicated that while all patients had received at least one vaccine dose, 95 tested positive for IgG and 25 were negative. A higher proportion of IgG-positive patients had received three vaccine doses. Comparatively, gamma-glutamyl transferase levels were elevated in IgM-negative patients. The study further differentiated patients based on their treatment status: 46 were treatment-naive and 74 had received chemotherapy combined with immune checkpoint inhibitors (ICT) at enrollment. Despite similar baseline characteristics and time from vaccination to antibody detection, IgM positivity was significantly lower in the ICT group, with no significant difference in IgG positivity between the treatment-naive and ICT groups. A multivariable analysis identified the number of vaccine doses as an independent factor of IgG positivity, while ICT emerged as an independent risk factor for IgM positivity. Additionally, IgG titers generally declined over time, although patients with higher baseline IgG levels maintained higher titers longer. In conclusion, ICT in patients with HNC does not significantly affect IgG levels post-vaccination. However, booster vaccinations have been shown to be associated with higher IgG positivity, although these levels gradually decrease over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-7945-6726</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care Unit, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Haoyu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Yujian</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3812-9120</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Xianlu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Guichan</ForeName><Initials>G</Initials><Identifier Source="ORCID">0009-0009-8285-3739</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Shaohang</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3765-9127</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lili</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuwei</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6990-2649</Identifier><AffiliationInfo><Affiliation>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2023A1515010464, 2022A1515012631, and 2022A1515110060</GrantID><Agency>Natural Science Foundation of Guangdong Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgG/IgM</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword><Keyword MajorTopicYN="N">head and neck cancer</Keyword><Keyword MajorTopicYN="N">immunochemotherapy</Keyword></KeywordList><CoiStatement>None of the authors have competing interests to disclose. The Figure 1 was created by Figdraw (www.figdraw.com, accessed on 14 September 2024).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>10</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39453261</ArticleId><ArticleId IdType="pmc">PMC11511189</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed9100234</ArticleId><ArticleId IdType="pii">tropicalmed9100234</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Q., Qin C., Liu M., Liu J. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: A systematic review and meta-analysis. Infect. Dis. Poverty. 2021;10:132. doi: 10.1186/s40249-021-00915-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00915-3</ArticleId><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahboob T., Ismail A.A., Shah M.R., Rahmatullah M., Paul A.K., Pereira M.L., Wiart C., Wilairatana P., Rajagopal M., Dolma K.G., et al. Development of SARS-CoV-2 Vaccine: Challenges and Prospects. Diseases. 2023;11:64. doi: 10.3390/diseases11020064.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diseases11020064</ArticleId><ArticleId IdType="pmc">PMC10123684</ArticleId><ArticleId IdType="pubmed">37092446</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao Y., Wu Y., Feng Y., Xu W., Xiong F., Zhang X. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. Front. Med. 2022;16:185–195. doi: 10.1007/s11684-021-0913-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-021-0913-y</ArticleId><ArticleId IdType="pmc">PMC8883005</ArticleId><ArticleId IdType="pubmed">35226300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ao L., Lu T., Cao Y., Chen Z., Wang Y., Li Z., Ren X., Xu P., Peng M., Chen M., et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV. Emerg. Microbes Infect. 2022;11:1126–1134. doi: 10.1080/22221751.2022.2059401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2059401</ArticleId><ArticleId IdType="pmc">PMC9037169</ArticleId><ArticleId IdType="pubmed">35369854</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Song R., Wang J., Zhang J., Cai H., He H., Hu W., Yu D., Wang C., Pan Q., et al. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer. Int. J. Infect. Dis. 2022;122:874–884. doi: 10.1016/j.ijid.2022.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.07.050</ArticleId><ArticleId IdType="pmc">PMC9316719</ArticleId><ArticleId IdType="pubmed">35905950</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai S., Liao G., Yu T., Gao Q., Zou L., Zhang H., Xu X., Chen J., Lu A., Wu Y., et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study. J. Med. Virol. 2022;94:4224–4233. doi: 10.1002/jmv.27872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27872</ArticleId><ArticleId IdType="pmc">PMC9347657</ArticleId><ArticleId IdType="pubmed">35585023</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Jawad S., Bau L., Alaguthurai T., Del M.D.B.I., Laing A.G., Hayday T.S., Monin L., Munoz-Ruiz M., McDonald L., Francos Q.I., et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021;39:257–275. doi: 10.1016/j.ccell.2021.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2021.01.001</ArticleId><ArticleId IdType="pmc">PMC7833668</ArticleId><ArticleId IdType="pubmed">33476581</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakkassery H., Carpenter E., Patten P., Irshad S. Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. Trends Mol. Med. 2022;28:1082–1099. doi: 10.1016/j.molmed.2022.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2022.07.006</ArticleId><ArticleId IdType="pmc">PMC9345889</ArticleId><ArticleId IdType="pubmed">35999131</ArticleId></ArticleIdList></Reference><Reference><Citation>Donhauser L.V., Veloso D.O.J., Schick C., Manlik W., Styblova S., Lutzenberger S., Aigner M., Philipp P., Robert S., Gandorfer B., et al. Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment. J. Immunother. Cancer. 2023;11:e007387. doi: 10.1136/jitc-2023-007387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2023-007387</ArticleId><ArticleId IdType="pmc">PMC10510941</ArticleId><ArticleId IdType="pubmed">37730271</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin L., Laing A.G., Munoz-Ruiz M., McKenzie D.R., Del M.D.B.I., Alaguthurai T., Domingo-Vila C., Hayday T.S., Graham C., Seow J., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: Interim analysis of a prospective observational study. Lancet Oncol. 2021;22:765–778. doi: 10.1016/S1470-2045(21)00213-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId><ArticleId IdType="pmc">PMC8078907</ArticleId><ArticleId IdType="pubmed">33930323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W., Chen H.D., Yu Y.W., Li N., Chen W.Q. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020. Chin. Med. J. 2021;134:783–791. doi: 10.1097/CM9.0000000000001474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000001474</ArticleId><ArticleId IdType="pmc">PMC8104205</ArticleId><ArticleId IdType="pubmed">33734139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21660</ArticleId><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lybaert W., Vermorken J.B. Editorial: Insights in head and neck cancer: 2021. Front. Oncol. 2023;13:1180965. doi: 10.3389/fonc.2023.1180965.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2023.1180965</ArticleId><ArticleId IdType="pmc">PMC10088214</ArticleId><ArticleId IdType="pubmed">37056347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumai T., Shinomiya H., Shibata H., Takahashi H., Kishikawa T., Okada R., Fujieda S., Sakashita M. Translational research in head and neck cancer: Molecular and immunological updates. Auris Nasus Larynx. 2024;51:391–400. doi: 10.1016/j.anl.2023.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anl.2023.08.006</ArticleId><ArticleId IdType="pubmed">37640594</ArticleId></ArticleIdList></Reference><Reference><Citation>Paderno A., Petrelli F., Lorini L., Capriotti V., Gurizzan C., Bossi P. The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis. Oral Oncol. 2024;153:106799. doi: 10.1016/j.oraloncology.2024.106799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2024.106799</ArticleId><ArticleId IdType="pubmed">38729036</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegand S., Wichmann G., Dietz A. Perspectives of Induction With Chemo and/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment. Front. Oncol. 2019;9:191. doi: 10.3389/fonc.2019.00191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00191</ArticleId><ArticleId IdType="pmc">PMC6443982</ArticleId><ArticleId IdType="pubmed">30972299</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice F., Musio D., Tombolini V. Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment. J. Pers. Med. 2021;11:393. doi: 10.3390/jpm11050393.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm11050393</ArticleId><ArticleId IdType="pmc">PMC8151395</ArticleId><ArticleId IdType="pubmed">34068797</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips R., Alnemri A., Amin D., Patel J., Topf M.C., Johnson J.M., BarAd V., Axelrod R., Argiris A., Fundakowski C., et al. Effect of preoperative programmed death-1 or programmed death ligand-1 immune check point inhibition on complications after surgery for primary head and neck cancer. Cancer-Am. Cancer Soc. 2023 doi: 10.1002/cncr.35045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cncr.35045</ArticleId><ArticleId IdType="pubmed">37788128</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns E.A., Muhsen I.N., Anand K., Xu J., Umoru G., Arain A.N., Abdelrahim M. Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors. J. Immunother. 2021;44:132–139. doi: 10.1097/CJI.0000000000000358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0000000000000358</ArticleId><ArticleId IdType="pmc">PMC7946380</ArticleId><ArticleId IdType="pubmed">33480637</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Z., Zhang J., Chen W., Zhou H., Du D., Zhu K., Chen H., Meng J., Yang J. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Infect. Dis. Poverty. 2023;12:87. doi: 10.1186/s40249-023-01128-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-023-01128-6</ArticleId><ArticleId IdType="pmc">PMC10515058</ArticleId><ArticleId IdType="pubmed">37736699</ArticleId></ArticleIdList></Reference><Reference><Citation>Spain L., Diem S., Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60. doi: 10.1016/j.ctrv.2016.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2016.02.001</ArticleId><ArticleId IdType="pubmed">26874776</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D.B., Nebhan C.A., Moslehi J.J., Balko J.M. Immune-checkpoint inhibitors: Long-term implications of toxicity. Nat. Rev. Clin. Oncol. 2022;19:254–267. doi: 10.1038/s41571-022-00600-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-022-00600-w</ArticleId><ArticleId IdType="pmc">PMC8790946</ArticleId><ArticleId IdType="pubmed">35082367</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau G., Yu M.L., Wong G., Thompson A. Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus? Hepatol. Int. 2022;16:482–483. doi: 10.1007/s12072-022-10318-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12072-022-10318-7</ArticleId><ArticleId IdType="pubmed">35229274</ArticleId></ArticleIdList></Reference><Reference><Citation>Au M., Rajagopalan A., Tee D., Philpott H. Immune checkpoint inhibitor colitis with concurrent cytomegalovirus reactivation. Intern. Med. J. 2022;52:504–505. doi: 10.1111/imj.15714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15714</ArticleId><ArticleId IdType="pubmed">35307927</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafayev K., Torres H. Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. Clin. Microbiol. Infect. 2022;28:1321–1327. doi: 10.1016/j.cmi.2022.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.02.042</ArticleId><ArticleId IdType="pubmed">35283317</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazer C. Checkpoint Inhibitor Immunotherapy for Head and Neck Cancer: Incorporating Care Step Pathways for Effective Side-Effect Management. J. Adv. Pract. Oncol. 2019;10((Suppl. S1)):37–46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7522658</ArticleId><ArticleId IdType="pubmed">33014516</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., Erfan J., Zabolotnyy D., Kienzer H.R., Cupissol D., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Eng. J. Med. 2008;359:1116–1127. doi: 10.1056/NEJMoa0802656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0802656</ArticleId><ArticleId IdType="pubmed">18784101</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiwert T.Y., Burtness B., Mehra R., Weiss J., Berger R., Eder J.P., Heath K., McClanahan T., Lunceford J., Gause C., et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956–965. doi: 10.1016/S1470-2045(16)30066-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(16)30066-3</ArticleId><ArticleId IdType="pubmed">27247226</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen E., Soulieres D., Le Tourneau C., Dinis J., Licitra L., Ahn M.J., Soria A., Machiels J.P., Mach N., Mehra R., et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 2019;393:156–167. doi: 10.1016/S0140-6736(18)31999-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31999-8</ArticleId><ArticleId IdType="pubmed">30509740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris R.L., Blumenschein G.J., Fayette J., Guigay J., Colevas A.D., Licitra L., Harrington K., Kasper S., Vokes E.E., Even C., et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N. Eng. J. Med. 2016;375:1856–1867. doi: 10.1056/NEJMoa1602252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1602252</ArticleId><ArticleId IdType="pmc">PMC5564292</ArticleId><ArticleId IdType="pubmed">27718784</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyt B.A., Baliga R., Sinclair A.M., Carroll S.F., Peterson M.S. Structure, Function, and Therapeutic Use of IgM Antibodies. Antibodies. 2020;9:53. doi: 10.3390/antib9040053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib9040053</ArticleId><ArticleId IdType="pmc">PMC7709107</ArticleId><ArticleId IdType="pubmed">33066119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Zhang H., Sun L. Therapeutic antibodies for COVID-19: Is a new age of IgM, IgA and bispecific antibodies coming? Mabs. 2022;14:2031483. doi: 10.1080/19420862.2022.2031483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2022.2031483</ArticleId><ArticleId IdType="pmc">PMC8890389</ArticleId><ArticleId IdType="pubmed">35220888</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C.M., Lenti M.V., Merli S., Di Sabatino A. Role of IgM Memory B Cells and Spleen Function in COVID-19. Front. Immunol. 2022;13:889876. doi: 10.3389/fimmu.2022.889876.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.889876</ArticleId><ArticleId IdType="pmc">PMC9280616</ArticleId><ArticleId IdType="pubmed">35844543</ArticleId></ArticleIdList></Reference><Reference><Citation>Uslu G.H., Rakici A.S., Yazici Z.A. COVID-19 vaccine immunity in oncology patients. Bratisl. Lek. Listy. 2023;124:187–192. doi: 10.4149/BLL_2023_030.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/BLL_2023_030</ArticleId><ArticleId IdType="pubmed">36598309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansourabadi A.H., Sadeghalvad M., Mohammadi-Motlagh H.R., Amirzargar A. Serological and Molecular Tests for COVID-19: A recent update. Iran. J. Immunol. 2021;18:13–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">33787511</ArticleId></ArticleIdList></Reference><Reference><Citation>Chvatal-Medina M., Mendez-Cortina Y., Patino P.J., Velilla P.A., Rugeles M.T. Antibody Responses in COVID-19: A Review. Front. Immunol. 2021;12:633184. doi: 10.3389/fimmu.2021.633184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.633184</ArticleId><ArticleId IdType="pmc">PMC8081880</ArticleId><ArticleId IdType="pubmed">33936045</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantuoyir M.M., Rezaei N. Serological tests for COVID-19: Potential opportunities. Cell Biol. Int. 2021;45:740–748. doi: 10.1002/cbin.11516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbin.11516</ArticleId><ArticleId IdType="pmc">PMC7753382</ArticleId><ArticleId IdType="pubmed">33289157</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieland E. Immunological Biomarkers in Blood to Monitor the Course and Therapeutic Outcomes of COVID-19. Ther. Drug Monit. 2022;44:148–165. doi: 10.1097/FTD.0000000000000945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FTD.0000000000000945</ArticleId><ArticleId IdType="pubmed">34840314</ArticleId></ArticleIdList></Reference><Reference><Citation>Arkhipova-Jenkins I., Helfand M., Armstrong C., Gean E., Anderson J., Paynter R.A., Mackey K. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity : A Rapid Living Review. Ann. Intern. Med. 2021;174:811–821. doi: 10.7326/M20-7547.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-7547</ArticleId><ArticleId IdType="pmc">PMC8025942</ArticleId><ArticleId IdType="pubmed">33721517</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornberg M., Buti M., Eberhardt C.S., Grossi P.A., Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J. Hepatol. 2021;74:944–951. doi: 10.1016/j.jhep.2021.01.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2021.01.032</ArticleId><ArticleId IdType="pmc">PMC7867401</ArticleId><ArticleId IdType="pubmed">33563499</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasapoglu B., Yozgat A., Tanoglu A., Can G., Sakin Y.S., Kekilli M. Gamma-glutamyl-transferase may predict COVID-19 outcomes in hospitalised patients. Int. J. Clin. Pract. 2021;75:e14933. doi: 10.1111/ijcp.14933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14933</ArticleId><ArticleId IdType="pmc">PMC8646326</ArticleId><ArticleId IdType="pubmed">34605109</ArticleId></ArticleIdList></Reference><Reference><Citation>Anupam S., Goel S., Bhatti K., Mehta D.K., Das R. Serum Gamma Glutamyl Transferase: Understanding its Contribution as a Potential Predictor of the Occurrence of Type 2 Diabetes. Curr. Diabetes Rev. 2024 doi: 10.2174/0115733998260996231122054907.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0115733998260996231122054907</ArticleId><ArticleId IdType="pubmed">38275034</ArticleId></ArticleIdList></Reference><Reference><Citation>Saco T.V., Strauss A.T., Ledford D.K. Hepatitis B vaccine nonresponders: Possible mechanisms and solutions. Ann. Allergy Asthma Immunol. 2018;121:320–327. doi: 10.1016/j.anai.2018.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.anai.2018.03.017</ArticleId><ArticleId IdType="pubmed">29567355</ArticleId></ArticleIdList></Reference><Reference><Citation>Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther. 2008;8:235–247. doi: 10.1517/14712598.8.2.235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.8.2.235</ArticleId><ArticleId IdType="pubmed">18194079</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdollahi A., Afsharyzad Y., Vaezi A., Meysamie A. Importance of the COVID-19 Vaccine Booster Dose in Protection and Immunity. Vaccines. 2022;10:1708. doi: 10.3390/vaccines10101708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101708</ArticleId><ArticleId IdType="pmc">PMC9610198</ArticleId><ArticleId IdType="pubmed">36298573</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali H., Alterki A., Sindhu S., Alahmad B., Hammad M., Al-Sabah S., Alghounaim M., Jamal M.H., Aldei A., Mairza M.J., et al. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination. Front. Immunol. 2021;12:752233. doi: 10.3389/fimmu.2021.752233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.752233</ArticleId><ArticleId IdType="pmc">PMC8652288</ArticleId><ArticleId IdType="pubmed">34899701</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasithsirikul W., Pongpirul K., Nopsopon T., Phutrakool P., Pongpirul W., Samuthpongtorn C., Suwanwattana P., Jongkaewwattana A. Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers. Vaccines. 2022;10:217. doi: 10.3390/vaccines10020217.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020217</ArticleId><ArticleId IdType="pmc">PMC8878194</ArticleId><ArticleId IdType="pubmed">35214675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaffanello M., Franchini M., Fanos V. Is serum Cystatin-C a suitable marker of renal function in children? Ann. Clin. Lab. Sci. 2007;37:233–240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17709686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahran A., El-Husseini A., Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am. J. Nephrol. 2007;27:197–205. doi: 10.1159/000100907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000100907</ArticleId><ArticleId IdType="pubmed">17361076</ArticleId></ArticleIdList></Reference><Reference><Citation>Babel N., Hugo C., Westhoff T.H. Vaccination in patients with kidney failure: Lessons from COVID-19. Nat. Rev. Nephrol. 2022;18:708–723. doi: 10.1038/s41581-022-00617-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00617-5</ArticleId><ArticleId IdType="pmc">PMC9397175</ArticleId><ArticleId IdType="pubmed">35999285</ArticleId></ArticleIdList></Reference><Reference><Citation>Soeiro E., Penido M., Palma L., Bresolin N.L., Lima E., Koch V., Tavares M.S., Sylvestre L., Bernardes R.P., Garcia C.D., et al. The challenges of the pandemic and the vaccination against covid-19 in pediatric patients with kidney disease. J. Bras. Nefrol. 2023;45:244–251. doi: 10.1590/2175-8239-jbn-2022-0081en.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/2175-8239-jbn-2022-0081en</ArticleId><ArticleId IdType="pmc">PMC10627141</ArticleId><ArticleId IdType="pubmed">36282106</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Zhou Y., Chen C., Fang W., Cai X., Zhang X., Zhao M., Zhang B., Jiang W., Lin Z., et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J. Immunother. Cancer. 2019;7:322. doi: 10.1186/s40425-019-0808-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-019-0808-5</ArticleId><ArticleId IdType="pmc">PMC6873745</ArticleId><ArticleId IdType="pubmed">31753012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lake A.C. Hepatitis B reactivation in a long-term nonprogressor due to nivolumab therapy. AIDS. 2017;31:2115–2118. doi: 10.1097/QAD.0000000000001599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000001599</ArticleId><ArticleId IdType="pubmed">28906278</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>